<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078126</url>
  </required_header>
  <id_info>
    <org_study_id>D5980C00023</org_study_id>
    <secondary_id>2019-001801-26</secondary_id>
    <nct_id>NCT04078126</nct_id>
  </id_info>
  <brief_title>Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.</brief_title>
  <official_title>A Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol Administered With a Spacer Compared With Symbicort® Turbuhaler® in Subjects With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Low Peak Inspiratory Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study comparing the same drugs as a dual combination product (budesonide and formoterol)&#xD;
      given via two different inhalers. To see which one results in the best effect on breathing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study&#xD;
      to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol&#xD;
      Administered with a Spacer Compared with Symbicort® Turbuhaler® in Subjects with Severe to&#xD;
      Very Severe Chronic Obstructive Pulmonary Disease and Low Peak Inspiratory Flow to assess&#xD;
      lung function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak change from baseline in FEV1 within 4 hours post-dose following 1 week of treatment</measure>
    <time_frame>4 hours post dose after 1 week of treatment</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on lung function, measured by peak forced expiratory volume in 1 second (FEV1) within 4 hours post-dose at Week 1, in subjects with COPD and low PIF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve for change from baseline in FEV1 from 0 to 4 hours (AUC0-4 h) following 1 week of treatment</measure>
    <time_frame>0 to 4 hours post dose after 1 week of treatment</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose FEV1 following 1 week of treatment</measure>
    <time_frame>1 week of treatment</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour post-dose inspiratory capacity (IC) following 1 week of treatment</measure>
    <time_frame>2 hours post dose after 1 week of treatment</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose PIF following 1 week of treatment</measure>
    <time_frame>1 week of treatment</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour post-dose FEV1 following the first dose</measure>
    <time_frame>1 day (2 hours)</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour post-dose IC following the first dose</measure>
    <time_frame>1 day (2 hours)</time_frame>
    <description>To assess the effects of BFF MDI administered with a spacer relative to Symbicort Turbuhaler on additional measures of lung function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Budesonide and formoterol fumarate (MDI BFF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject treated with MDI BFF followed by washout period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject treated with Symbicort followed by washout period</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>BFF</intervention_name>
    <description>Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)</description>
    <arm_group_label>Budesonide and formoterol fumarate (MDI BFF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Symbicort Turbuhaler</intervention_name>
    <description>Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)</description>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be 40 to 80 years of age inclusive, at the time of signing the ICF.&#xD;
&#xD;
          2. Individuals who have a physician diagnosis of COPD as defined by the American Thoracic&#xD;
             Society (ATS)/European Respiratory Society (ERS)&#xD;
&#xD;
          3. Require COPD maintenance therapy: all subjects must be receiving 2 or more inhaled&#xD;
             maintenance therapies, including at least 1 long-acting bronchodilator, for the&#xD;
             management of their COPD for at least 4 weeks prior to Visit 1.&#xD;
&#xD;
          4. A post-bronchodilator FEV1/FVC of &lt;0.70 and post-bronchodilator FEV1 of &lt;50% predicted&#xD;
             normal value at Visit 2.&#xD;
&#xD;
          5. A pre-bronchodilator PIF of &lt;50 L/min using the InCheck Inspiratory Flow Measurement&#xD;
             Device set to Turbuhaler S resistance at Visit 2.&#xD;
&#xD;
          6. Current or former smokers with history of at least 10 pack-years of cigarette smoking.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Current diagnosis of asthma, in the opinion of the Investigator.&#xD;
&#xD;
          2. Other respiratory disorders including known active tuberculosis, lung cancer, cystic&#xD;
             fibrosis, significant bronchiectasis (high resolution CT evidence of bronchiectasis&#xD;
             that causes repeated acute exacerbations), immune deficiency disorders, severe&#xD;
             neurological disorders affecting control of the upper airway, sarcoidosis, idiopathic&#xD;
             interstitial pulmonary fibrosis, primary pulmonary hypertension, or pulmonary&#xD;
             thromboembolic disease.&#xD;
&#xD;
          3. A moderate or severe exacerbation of COPD ending within 6 weeks prior to randomization&#xD;
             (Visit 3).&#xD;
&#xD;
          4. Need for mechanical ventilation within 3 months prior to Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bärbel Huber, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2601</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heiner Steffen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2602</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Keller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2603</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Hoffmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2604</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>D-30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Landsberg</city>
        <zip>86899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

